GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 130,500
+3,400 (2.68%)
Aug 28, 2026, 3:30 PM KST
GC Biopharma Revenue
GC Biopharma had revenue of 435.53B KRW in the quarter ending March 31, 2026, with 13.49% growth. This brings the company's revenue in the last twelve months to 2.04T, up 19.70% year-over-year. In the year 2025, GC Biopharma had annual revenue of 1.99T with 18.54% growth.
Revenue (ttm)
2.04T
Revenue Growth
+19.70%
P/S Ratio
0.71
Revenue / Employee
1.00B
Employees
2,042
Market Cap
1.45T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.99T | 311.39B | 18.54% |
| Dec 31, 2024 | 1.68T | 53.25B | 3.27% |
| Dec 31, 2023 | 1.63T | -84.67B | -4.95% |
| Dec 31, 2022 | 1.71T | 173.49B | 11.28% |
| Dec 31, 2021 | 1.54T | 33.71B | 2.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.12T |
| Chong Kun Dang Pharmaceutical | 1.74T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.06T |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |
| Celltrion Pharm | 274.73B |
GC Biopharma News
- 10 months ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn